CoChat

Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential

Open access

The DOI matches its Crossref record; 507 of the 508 references it cites were found in a registry or an index; 253 of the 449 sources its claims cite were checked for support.

Abstract

Major depressive disorder (MDD) is a chronic, generally episodic and debilitating disease that affects an estimated 300 million people worldwide, but its pathogenesis is poorly understood. The heritability estimate of MDD is 30-40%, suggesting that genetics alone do not account for most of the risk of major depression. Another factor known to associate with MDD involves environmental stressors such as childhood adversity and recent life stress. Recent studies have emerged to show that the biological impact of environmental factors in MDD and other stress-related disorders is mediated by a variety of epigenetic modifications. These epigenetic modification alterations contribute to abnormal neuroendocrine responses, neuroplasticity impairment, neurotransmission and neuroglia dysfunction, which are involved in the pathophysiology of MDD. Furthermore, epigenetic marks have been associated with the diagnosis and treatment of MDD. The evaluation of epigenetic modifications holds promise for further understanding of the heterogeneous etiology and complex phenotypes of MDD, and may identify new therapeutic targets. Here, we review preclinical and clinical epigenetic findings, including DNA methylation, histone modification, noncoding RNA, RNA modification, and chromatin remodeling factor in MDD. In addition, we elaborate on the contribution of these epigenetic mechanisms to the pathological trait variability in depression and discuss how such mechanisms can be exploited for therapeutic purposes.

Overview

CoChat Summary

TL;DR

This review synthesizes preclinical and clinical evidence that epigenetic mechanisms—DNA methylation, histone modifications, noncoding RNAs, RNA modifications, and chromatin remodeling—mediate the biological impact of environmental stressors in major depressive disorder (MDD) and other stress-related disorders. It argues these marks contribute to neuroendocrine, neuroplasticity, neurotransmission, and neuroglial dysfunction, and may serve as diagnostic, treatment-response, and therapeutic targets.

Key findings

  • MDD heritability is estimated at ~35%, lower than schizophrenia or bipolar disorder (65–70%); GWAS has identified over 80 reproducible loci each with small effect, and polygenic risk scores explain only a small fraction of heritable risk—supporting a substantial environmental/epigenetic contribution.
  • DNA methylation findings are heterogeneous and location-dependent: promoter CpG island methylation generally suppresses expression (e.g., BDNF promoter methylation correlating with decreased BDNF), but gene-body and non-proximal promoter methylation can enhance expression; early-life adversity is linked to GR (NR3C1) promoter hypermethylation in hippocampus, and childhood adversity before age three explains more DNA methylation variability than accumulation or recency of exposure.
  • Histone modification evidence is brain-region-specific and sometimes contradictory: HDAC2 and HDAC5 show pro-depressive effects in hippocampus but opposite (pro-resilient/homeostatic) roles in NAc and amygdala; stress-induced depression is generally associated with decreased histone acetylation, and HDAC inhibitors (e.g., MS-275, SAHA, sodium butyrate) exert antidepressant-like effects in rodents.
  • ncRNAs and RNA modifications are altered in MDD and by antidepressants: e.g., miR-1202 rises after 8 weeks of citalopram; escitalopram altered 30 miRNAs; ketamine downregulated 18 and upregulated 22 miRNAs in rats; FTO rs9939609 was associated with lower MDD risk, and ALKBH5 rs12936694 showed allelic and genotypic association with MDD.

Methods

  • Narrative review of preclinical (rodent stress models: early life stress, chronic social defeat, chronic unpredictable mild stress) and clinical (postmortem brain, peripheral blood, saliva, buccal cells) epigenetic findings in MDD and stress-related disorders.
  • Covers five epigenetic categories: DNA methylation/hydroxymethylation, histone modification, noncoding RNAs (miRNA, circRNA, lncRNA), RNA modification (chiefly m6A, plus ac4C and m5C), and ATP-dependent chromatin remodeling.
  • Includes three summary tables: DNA methylation alterations with clinical/biological outcomes (Table 1), candidate diagnostic epigenetic biomarkers (Table 2), biomarkers predicting antidepressant response (Table 3), and drugs targeting epigenetic processes (Table 4).

Limitations

  • Stated by the paper: most literature does not distinguish DNA methylation from hydroxymethylation, and bisulfite-based assays measure both indiscriminately; most DNA methylation markers in peripheral tissue cannot accurately predict brain methylation status; clinical studies cannot separate whether fluctuating biology reflects homeostatic response, illness-severity stress, or pathophysiology; most histone modification studies examine heterogeneous cell populations; few clinical studies address histone modifications; and clinical adaptation of HDAC/DNMT inhibitors is constrained by off-target effects given their wide CNS and peripheral distribution.
  • Evident from the text: the review is narrative rather than systematic, with no stated search strategy, inclusion criteria, or quantitative synthesis; many cited findings rest on small samples (the paper itself notes one replication study had a small sample size); and much of the mechanistic evidence derives from animal models, with the authors repeatedly noting that human relevance and causality remain to be established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-023-01519-z

Cites

507 of 507 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Overview of the role of epigenetic processes on the pathophysiology of stress-related disorders. Environmental factors, including early life stress, childhood trauma, and stressful life events in adulthood contribute to the development of stress-related disorders through direct epigenetic regulation or gene-by-environment interactions. Epigenetic mechanisms include chromatin structure changes, histone modifications, DNA modification, noncoding RNA changes, and RNA modifications. These epigenetic processes play crucial roles in different aspects of the pathophysiology of stress-related disorders
Fig. 1 Overview of the role of epigenetic processes on the pathophysiology of stress-related disorders. Environmental factors, including early life stress, childhood trauma, and stressful life events in adulthood contribute to the development of stress-related disorders through direct epigenetic regulation or gene-by-environment interactions. Epigenetic mechanisms include chromatin structure changes, histone modifications, DNA modification, noncoding RNA changes, and RNA modifications. These epigenetic processes play crucial roles in different aspects of the pathophysiology of stress-related disordersCC BY · PubMed Central
Fig. 2 DNA methylation is involved in the progression of MDD and stress-related disorders. DNA methylation is a biological process by which methyl groups are added to the DNA at position 5′ in cytosine (5mC), which is mainly found at CpG dinucleotides. In contrast to DNA methylation, which is set up by methyltransferases (DNMT3A and DNMT3B) and maintained by DNMT1, 5mC is oxidized to 5hmC by the ten-eleven translocation (TET) family of dioxygenase proteins. In successive steps, TET enzymes further hydroxylate 5hmC to 5fC and then 5caC, which are recognized and removed by TDG, generating an unmodified cytosine. Many clinical and animal studies have examined DNA methylation of genes involved in multiple biological pathways. 5mC methylation at position 5′ in the cytosine, DNMT DNA methyltransferase, TET ten-eleven translocation, 5hmC 5-hydroxymethylcytosine, 5fC 5-formylcytosine, 5caC 5-carboxylcytosine, TDG thymine-DNA glycosylase
Fig. 2 DNA methylation is involved in the progression of MDD and stress-related disorders. DNA methylation is a biological process by which methyl groups are added to the DNA at position 5′ in cytosine (5mC), which is mainly found at CpG dinucleotides. In contrast to DNA methylation, which is set up by methyltransferases (DNMT3A and DNMT3B) and maintained by DNMT1, 5mC is oxidized to 5hmC by the ten-eleven translocation (TET) family of dioxygenase proteins. In successive steps, TET enzymes further hydroxylate 5hmC to 5fC and then 5caC, which are recognized and removed by TDG, generating an unmodified cytosine. Many clinical and animal studies have examined DNA methylation of genes involved in multiple biological pathways. 5mC methylation at position 5′ in the cytosine, DNMT DNA methyltransferase, TET ten-eleven translocation, 5hmC 5-hydroxymethylcytosine, 5fC 5-formylcytosine, 5caC 5-carboxylcytosine, TDG thymine-DNA glycosylaseCC BY · PubMed Central
Fig. 3 Different types of histone modification changes in different brain regions in stressed animals and depressed humans. a Animal models and behavior analyses for studying the relationship between stress vulnerability to epigenetic changes and depression. Recent studies using animal models show brain region-specific histone modification changes. The NAc104,130,158,167,168,211 and hippocampus136,137,148,170,175,513 are the most studied brain regions for histone modification, with both consistent and conflicting findings across different studies. Different types of histone modification are also observed in other brain regions, such as the prefrontal cortex175. b Histone modification changes based on human postmortem tissue130,158,165,168 and peripheral blood, collected in both cases from depressed individuals159,160. c Chemical reactions involved in histone acetylation and methylation. NAc nucleus accumbens, CoA crotonyl-coenzyme A, HDAC histone deacetylases, HAT histone acetyl transferases, SAM S-adenosyl methionine, HMT histone methyltransferases, HDM histone demethylases, SAH S-adenosyl homocysteine, α-KG α-ketoglutarate. ↑ Increased changes compared with controls; ↓ decreased changes compared with controls; ↑↓ both increased and decreased changes were reported across different studies
Fig. 3 Different types of histone modification changes in different brain regions in stressed animals and depressed humans. a Animal models and behavior analyses for studying the relationship between stress vulnerability to epigenetic changes and depression. Recent studies using animal models show brain region-specific histone modification changes. The NAc104,130,158,167,168,211 and hippocampus136,137,148,170,175,513 are the most studied brain regions for histone modification, with both consistent and conflicting findings across different studies. Different types of histone modification are also observed in other brain regions, such as the prefrontal cortex175. b Histone modification changes based on human postmortem tissue130,158,165,168 and peripheral blood, collected in both cases from depressed individuals159,160. c Chemical reactions involved in histone acetylation and methylation. NAc nucleus accumbens, CoA crotonyl-coenzyme A, HDAC histone deacetylases, HAT histone acetyl transferases, SAM S-adenosyl methionine, HMT histone methyltransferases, HDM histone demethylases, SAH S-adenosyl homocysteine, α-KG α-ketoglutarate. ↑ Increased changes compared with controls; ↓ decreased changes compared with controls; ↑↓ both increased and decreased changes were reported across different studiesCC BY · PubMed Central
Fig. 4 Noncoding RNA in depression: generation, mechanisms of function, and effects. DNA constitutes an essential part of the human genome and contributes to the formation of noncoding RNA after transcription. For lncRNAs, multiple mechanisms are involved in the pathophysiology of depression: transcriptional activation: lncRNAs can activate the expression of target genes via (1) recruiting transcriptional factors to upstream open reading frames; (2) suppressing transcriptional factors to upstream open reading frames; (3) recruiting chromatin modifying factors to alter chromatin structure; (4) suppressing interacting proteins and RNP-complexes to target genes. For circRNAs, they are generated from back-splicing and canonical splicing of an mRNA transcript. These circRNAs are associated with homer scaffolding protein 1, regulate cell proliferation, and inhibit JAK2/STAT3 signal, leading to neuropathological changes related to depression. For miRNAs, multiple mechanisms, including mRNA degradation or inhibition by the RISC complex, activate depression. These mechanisms induce gene expression changes, which are associated with several molecular pathways of depression. RISC RNA-induced silencing complex, RNP ribonucleoprotein complexes, STAT3 signal transducer and activator of transcription 3, SERT serotonin transporter, BDNF brain-derived neurotrophic factor, GR glucocorticoid receptor, JAK2-STAT3 Janus kinase 2 and signal transducer and activator of transcription 3
Fig. 4 Noncoding RNA in depression: generation, mechanisms of function, and effects. DNA constitutes an essential part of the human genome and contributes to the formation of noncoding RNA after transcription. For lncRNAs, multiple mechanisms are involved in the pathophysiology of depression: transcriptional activation: lncRNAs can activate the expression of target genes via (1) recruiting transcriptional factors to upstream open reading frames; (2) suppressing transcriptional factors to upstream open reading frames; (3) recruiting chromatin modifying factors to alter chromatin structure; (4) suppressing interacting proteins and RNP-complexes to target genes. For circRNAs, they are generated from back-splicing and canonical splicing of an mRNA transcript. These circRNAs are associated with homer scaffolding protein 1, regulate cell proliferation, and inhibit JAK2/STAT3 signal, leading to neuropathological changes related to depression. For miRNAs, multiple mechanisms, including mRNA degradation or inhibition by the RISC complex, activate depression. These mechanisms induce gene expression changes, which are associated with several molecular pathways of depression. RISC RNA-induced silencing complex, RNP ribonucleoprotein complexes, STAT3 signal transducer and activator of transcription 3, SERT serotonin transporter, BDNF brain-derived neurotrophic factor, GR glucocorticoid receptor, JAK2-STAT3 Janus kinase 2 and signal transducer and activator of transcription 3CC BY · PubMed Central
Fig. 5 Functional mechanisms of representative miRNAs involved in depression. A variety of miRNAs can influence neurodevelopment, synaptic plasticity and neurotransmitters by regulating their target genes, thus leading to depression. PTEN phosphatase and tensin homolog deleted on chromosome ten, PI3K phosphoinositide 3-kinase, GRM metabotropic glutamate receptor, mEPSC/sEPSC miniature excitatory postsynaptic current/spontaneous excitatory postsynaptic current, SERT serotonin transporter, BDNF brain-derived neurotrophic factor
Fig. 5 Functional mechanisms of representative miRNAs involved in depression. A variety of miRNAs can influence neurodevelopment, synaptic plasticity and neurotransmitters by regulating their target genes, thus leading to depression. PTEN phosphatase and tensin homolog deleted on chromosome ten, PI3K phosphoinositide 3-kinase, GRM metabotropic glutamate receptor, mEPSC/sEPSC miniature excitatory postsynaptic current/spontaneous excitatory postsynaptic current, SERT serotonin transporter, BDNF brain-derived neurotrophic factorCC BY · PubMed Central
Fig. 6 Schematic diagram illustrating how the molecular basis of m6A and other reported RNA modifications relates to depression. The modification of m6A in MDD is regulated by the action of a complex network of proteins: “writers”, which include METTL3, METTL14, WTAP and RBM15–methylate RNA; “erasers”, which include ALKBH5 and FTO–demethylate RNA; and “readers”, which include eIF3, YTHDF1, IGF2BPs and HNRNPA2B1-recognize m6A. Other RNA modifications associated with MDD include N4-acetylcytidine (ac4C) and 5-methylcytosine (m5C). NAT10 can regulate mRNA translation efficiency by catalyzing ac4C while NSUN catalyzes m5C. The molecular consequences of these enzymes involve a variety of pathophysiological mechanisms related to MDD. METTL3 methyltransferase-like 3, METTL14 methyltransferase-like 14, WTAP Wilms tumor 1-associated protein, RBM15 RNA-binding motif protein 15, FTO obesity-associated protein, ALKBH5 Alkb homolog 5, eIF3 eukaryotic initiation factor 3, YTHDF1 YT521-B homology N6-Methyladenosine RNA Binding Protein 1, IGF2BPs insulin-like growth factor 2 mRNA binding proteins, CGC cerebellar granule cells, SIRT sirtuin, Adrb2 Adrenoceptor 2, CRY1/2 circadian regulator cryptochrome 1 and 2, FAAH fatty acid amide hydrolase, LRP2 lipoprotein receptor-related protein 2, Gab1s growth factor receptor-bound protein 2 associated binding protein 1
Fig. 6 Schematic diagram illustrating how the molecular basis of m6A and other reported RNA modifications relates to depression. The modification of m6A in MDD is regulated by the action of a complex network of proteins: “writers”, which include METTL3, METTL14, WTAP and RBM15–methylate RNA; “erasers”, which include ALKBH5 and FTO–demethylate RNA; and “readers”, which include eIF3, YTHDF1, IGF2BPs and HNRNPA2B1-recognize m6A. Other RNA modifications associated with MDD include N4-acetylcytidine (ac4C) and 5-methylcytosine (m5C). NAT10 can regulate mRNA translation efficiency by catalyzing ac4C while NSUN catalyzes m5C. The molecular consequences of these enzymes involve a variety of pathophysiological mechanisms related to MDD. METTL3 methyltransferase-like 3, METTL14 methyltransferase-like 14, WTAP Wilms tumor 1-associated protein, RBM15 RNA-binding motif protein 15, FTO obesity-associated protein, ALKBH5 Alkb homolog 5, eIF3 eukaryotic initiation factor 3, YTHDF1 YT521-B homology N6-Methyladenosine RNA Binding Protein 1, IGF2BPs insulin-like growth factor 2 mRNA binding proteins, CGC cerebellar granule cells, SIRT sirtuin, Adrb2 Adrenoceptor 2, CRY1/2 circadian regulator cryptochrome 1 and 2, FAAH fatty acid amide hydrolase, LRP2 lipoprotein receptor-related protein 2, Gab1s growth factor receptor-bound protein 2 associated binding protein 1CC BY · PubMed Central
Fig. 7 Targeting epigenetic modifications by potential antidepressants and relevant behavioral changes observed in rodents. a Different HDAC inhibitors, including MS-275, sodium, and butyrate can block histone deacetylation and promote the expression of target genes. DNMT inhibitors, including cannabidiol, s-adenosyl methionine and quetiapine activate DNA demethylation patterns to promote the expression of target genes. b These epigenetic variations lead to important recovery in the neural circuits, synaptic plasticity, astrocyte morphological changes, etc. c Improved depression-like behaviors in rodents after implementing drugs interfering with epigenetic mechanisms
Fig. 7 Targeting epigenetic modifications by potential antidepressants and relevant behavioral changes observed in rodents. a Different HDAC inhibitors, including MS-275, sodium, and butyrate can block histone deacetylation and promote the expression of target genes. DNMT inhibitors, including cannabidiol, s-adenosyl methionine and quetiapine activate DNA demethylation patterns to promote the expression of target genes. b These epigenetic variations lead to important recovery in the neural circuits, synaptic plasticity, astrocyte morphological changes, etc. c Improved depression-like behaviors in rodents after implementing drugs interfering with epigenetic mechanismsCC BY · PubMed Central

Verification

Claims the paper makes

182 Valid · 15 Not valid · 108 Not checked · 26 Own results and interpretations

180 more claims · 118 with their cited sources checked

Create a free account to see all 331 claims and to verify the 18 references still open.

See all claims — free account
  • It may state two separate claims as one. 116
  • Probably not a substantial claim. 44

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 507 references

Research works printed but not linked: 7

  1. Monroe, S. M., Slavich, G. M. & Georgiades, K. in Handbook of Depression 3rd ed. 296–314 (The Guilford Press, 2014).
  2. Morello, N. et al. Effects of forced swimming stress on ERK and histone H3 phosphorylation in limbic areas of Roman high-and low-avoidance rats. PLoS ONE 12, e0170093 (2017). · DOI · Paper page
  3. McKay, M. T. et al. Childhood trauma and adult mental disorder: a systematic review and metaoanalysis of longitudinal cohort studies. Acta Psychiatr. Scand. 143, 189–205 (2021). · DOI · Paper page
  4. Higuchi, Y., Soga, T. & Parhar, I. S. Potential roles of microRNAs in the regulation of monoamine oxidase A in the brain. Front. Mol. Neurosci. 11, 339 (2018). · DOI · Paper page
  5. Wan, Y. Q. et al. Prefrontal cortex miR-29b-3p plays a key role in the antidepressant-like effect of ketamine in rats. Exp. Mol. Med. 50, 1–14 (2018). · DOI · Paper page
  6. Li, J., Meng, H., Cao, W. & Qiu, T. MiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4. Neurosci. Lett. 606, 167–172 (2015). · DOI · Paper page
  7. Domschke, K. et al. Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response. J. Neural Transm. 122, 99–108 (2015). · DOI

Cited by

See all 246

Metadata

Authors
Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W.
Affiliations
  • Sichuan University (CN)
  • Columbia University (US)
  • New York State Psychiatric Institute (US)
  • Eastern Virginia Medical School (US)
  • Ningbo University (CN)
Corresponding author
  • Wang, Chuang
  • Zhang, Wei
Venue
Signal Transduction and Targeted Therapy
Published
2023-08-30
Volume
8
Issue
1
Pages
309-309
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4386241957
Cited by
246
References
508
Citations by year
2026: 102 · 2025: 85 · 2024: 57 · 2023: 2
FWCI
6.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (#81821002, 82200695, 82120108002, ZYJC21004, ZYGD22007, 2021ZD0201900, 82171527)
  • Ministry of Science and Technology of the People's Republic of China (2021ZD0201900)
  • Sichuan University (ZYGD22007, ZYJC21004)
  • West China Hospital, Sichuan University (ZYJC21004, ZYGD22007)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
major depressive disorder, epigenetic regulation, stress-related disorders, DNA methylation, histone modifications, non-coding RNA, RNA modification, chromatin remodeling, childhood adversity, life events, neuroendocrine response, neuroplasticity, depression heterogeneity, depression biomarkers
MeSH terms
Clinical Relevance, Depression, Major Depressive Disorder, Humans, DNA Methylation, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential. https://app.cochat.ai/papers/10.1038/s41392-023-01519-z
The paper
Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W. (2023). Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-023-01519-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.